Skip to main content

Advertisement

SpringerLink
Log in

The value of circulating CYFRA21-1 expression in patients with nasopharyngeal carcinoma: a study of 529 subjects

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Early diagnosis of nasopharyngeal carcinoma (NPC) needs more reliable biomarkers. The aim of this study was to investigate serum cytokeratin 19 fragment 21.1 (CYFRA21-1) as an NPC biomarker based on data from a large sample.

Methods

From October 2010 to February 2014, 529 subjects were enrolled and divided into three groups—NPC group (n = 274), healthy control group (n = 175) and nasal inflammatory disease group (n = 80). Serum CYFRA21-1 levels were measured prior to radiotherapy/chemoradiotherapy, and their associations with T, N, and clinical classification were determined. Receiver operating characteristic curve analysis was performed to discriminate the NPC group from the healthy control and nasal inflammatory disease groups. Three Epstein–Barr virus (EBV) antibodies and their correlations with serum CYFRA21-1 levels were analyzed.

Results

Pretreatment serum CYFRA21-1 levels were significantly elevated in the NPC group compared with the other groups (p < 0.01), Furthermore, serum CYFRA21-1 levels decreased significantly after radiotherapy (p < 0.01). Serum CYFRA21-1 levels were closely related to T, N, and clinical classifications. The area under the curve, sensitivity and specificity of the serum CYFRA21-1 levels in the NPC patients were 0.89, 0.87 and 0.83, respectively. Strong correlations were observed between serum CYFRA21-1 levels and EBV antibodies.

Conclusion

Serum CYFRA21-1 may be a reliable and effective biomarker for NPC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Wu SY, Wu YH, Yang MW et al (2014) Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up. BMC Cancer 14:787

    Article  PubMed  PubMed Central  Google Scholar 

  2. Su FR, Ding JH, Bo L et al (2014) Chromodomain helicase/ATPase DNA binding protein 1-like protein expression predicts poor prognosis in nasopharyngeal carcinoma. Exp Ther Med 8(6):1745–1750

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Raab-Traub N (2002) Epstein–Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12(6):431–441

    Article  CAS  PubMed  Google Scholar 

  4. Lee AW, Lin JC, Ng WT (2012) Current management of nasopharyngeal cancer. Semin Radiat Oncol 22(3):233–244

    Article  PubMed  Google Scholar 

  5. Leung SF, Chan KC, Ma BB et al (2014) Plasma Epstein–Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 24:1204–1208

    Article  Google Scholar 

  6. Ji MF, Huang Qh, Yu X et al (2014) Evaluation of plasma Epstein–Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China. Cancer 120(9):1353–1360

    Article  CAS  PubMed  Google Scholar 

  7. Arai T, Inoue Y, Sugimoto C et al (2014) CYFRA 21-1 as a disease severity marker for autoimmune pulmonary alveolar proteinosis. Respirology 19(2):246–252

    Article  PubMed  Google Scholar 

  8. Ono A, Takahashi T, Mori K et al (2013) Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer 13:354

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hanagiri T, Sugaya M, Takenaka M et al (2011) Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer 74(1):112–117

    Article  PubMed  Google Scholar 

  10. Nisman B, Biran H, Heching N et al (2008) Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. Br J Cancer 98(1):77–79

    Article  CAS  PubMed  Google Scholar 

  11. Wei Z, Zeng X, Xu J et al (2014) Prognostic value of the pretreatment serum level of cytokeratin fraction 21-1 in undifferentiated nasopharyngeal carcinoma: a study of 332 cases. Head Neck 36(1):71–76

    Article  PubMed  Google Scholar 

  12. Lin WY, Yen TC, Cheng KY et al (1998) The value of CYFRA 21-1, a new tumor marker, in nasopharyngeal carcinoma. Neoplasma 45(1):21–24

    CAS  PubMed  Google Scholar 

  13. Song XM, Wang SZ, Wang ZJ et al (2015) Serum CYFRA21-1 as an effective tumor biomarker for patients with nasopharyngeal carcinoma. Neoplasma 62(1):124–129

    Article  CAS  PubMed  Google Scholar 

  14. Wang SZ, Li J, Miyamoto CT et al (2009) A study of middle ear function in the treatment of nasopharyngeal carcinoma with IMRT technique. Radiother Oncol 93(3):530–533

    Article  PubMed  Google Scholar 

  15. Sheard MA, Vojtesek B, Simickova M et al (2002) Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem 85(4):670–677

    Article  CAS  PubMed  Google Scholar 

  16. Kosacka M, Jankowska R (2009) Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer. Pol Arch Med Wewn 119(1–2):33–37

    CAS  PubMed  Google Scholar 

  17. Liu L, Liu B, Zhu L-L et al (2013) CYFRA21-1 as a serum tumor marker for follow-up patients with squamous cell lung carcinoma and oropharynx squamous cell carcinoma. Biomark Med 7(4):591–599

    Article  CAS  PubMed  Google Scholar 

  18. Holdenrieder S, von Pawel J, Dankelmann E et al (2008) Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res 14(23):7813–7821

    Article  CAS  PubMed  Google Scholar 

  19. Cao X, Zhang L, Feng G-R et al (2012) Preoperative Cyfra21-1 and SCC-Ag serum titers predict survival in patients with stage II esophageal squamous cell carcinoma. J Transl Med 10:197

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Boeck S, Wittwer C, Heinemann V et al (2013) Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. Br J Cancer 108(8):1684–1694

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Satyam A, Singh P, Sharma M et al (2011) CYFRA 21-1: a potential molecular marker for noninvasive differential diagnosis of urothelial carcinoma of bladder. Biomarkers 16(5):413–421

    Article  CAS  PubMed  Google Scholar 

  22. Zhu WQ, Yu JM, Sun XD et al (2010) Serum CYFRA21-1 as a prognostic marker for patients with undifferentiated nasopharyngeal carcinoma. Biomarkers 15(7):602–607

    Article  CAS  PubMed  Google Scholar 

  23. Wu H, Kapoor P, Frappier L (2002) Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein–Barr nuclear antigen 1. J Virol 76(5):2480–2490

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Yu KJ, Hsu WL, Pfeiffer RM et al (2011) Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families. Clin Cancer Res 17(7):1906–1914

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Liu Y, Huang Q, Liu W et al (2012) Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. Int J Cancer 131(2):406–416

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This project was supported by funds from the People’s Republic of China Ministry of Science and Technology. The Project Number is 2011ZX09101-001.

Author information

Author notes

    Authors and Affiliations

    1. Department of Radiation Oncology, Eye, Ear, Nose and Throat, FuDan University, Fenyang Road 83, Shanghai, 200031, China

      Xin-mao Song,  Ji-Li, Fu Chen & Sheng-zi Wang

    2. Department of Clinical Laboratory, Eye, Ear, Nose and Throat, FuDan University, Fenyang Road 83, Shanghai, 200031, China

      Zhu-jian Wang & Wen-jun Cao

    Authors
    1. Xin-mao Song
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Zhu-jian Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Wen-jun Cao
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Ji-Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Fu Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Sheng-zi Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Sheng-zi Wang.

    Ethics declarations

    Conflict of interest

    All authors declared they had no conflict of interest.

    Additional information

    X. Song and Z. Wang contributed equally and are co-first authors.

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Song, Xm., Wang, Zj., Cao, Wj. et al. The value of circulating CYFRA21-1 expression in patients with nasopharyngeal carcinoma: a study of 529 subjects. Int J Clin Oncol 21, 1038–1045 (2016). https://doi.org/10.1007/s10147-016-1020-y

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s10147-016-1020-y

    Keywords

    Search

    Navigation